DHA supplementation for late onset Stargardt disease: NAT-3 study

We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD).

DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BCVA) and multifocal electroretinogram (mfERG), was performed at inclusion day 0 (D0) and at month 6 (M6).

Overall, no statistical differences have been observed at M6 vs D0 as regards BCVA and mfERG (P > 0.05). Mild Improvement of BCVA and improvement of mfERG was noted in seven/40 eyes of four/20 patients. In the first patient, the peak of the a wave increased from 66 nV/deg(2) to 75.4 nV/deg(2) in the right eye (RE) and 24.5 nV/deg(2) to 49.1 nV/deg(2) in the left eye (LE). The peak of the b wave improved from 122 nV/deg(2) to 157 nV/deg(2) in the RE, and 102 nV/deg(2) to 149 nV/deg(2) in the LE. In the second patient peaks of the a and b waves respectively increased from 11.8 nV/deg(2) to 72.1 nV/deg(2) and 53 nV/deg(2) to 185 nV/deg(2) in the RE. In the third patient the peak of the a wave increased from 37 nV/deg(2) to 43 nV/deg(2) in the RE, and from 31 nV/deg(2) to 45 nV/deg(2) in the LE; the peak of the b wave improved from 70 nV/deg(2) to 89 nV/deg(2) in the RE, and from 101 nV/deg(2) to 108 nV/deg(2) in the LE. In the fourth patient, the peak of the a wave increased from 39 nV/deg(2) to 42 nV/deg(2) in the RE, and from 40 nV/deg(2) to 43 nV/deg(2) in the LE; the peak of the b wave improved from 86 nV/deg(2) to 94 nV/deg(2) in the RE, and from 87 nV/deg(2) to 107 nV/deg(2) in the LE.

DHA seems to influence some functional parameters in patients affected with STGD. However, no short-term benefit should be expected from DHA supplementation.